At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ENGN ENGENE HOLDINGS INC
Pre-Mkt 01-02 07:40:35 EST
9.03
+0.08
+0.89%
High9.16Low8.62Vol103.09K
Open9.16D1 Closing8.95Amplitude6.04%
Mkt Cap604.87MTradable Cap337.12MTotal Shares66.98M
T/O924.50KT/O Rate0.28%Tradable Shares37.33M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

EnGene Fiscal 2025 Loss Widens
MT Newswires Live  ·  2025-12-23
EnGene Fiscal 2025 Loss Widens
enGene Holdings Q4 EPS $(0.73) Misses $(0.57) Estimate
Benzinga  ·  2025-12-23
enGene Holdings Q4 EPS $(0.73) Misses $(0.57) Estimate
enGene reports FY net loss of USD 117.3 million, more than double year-on-year
Reuters  ·  2025-12-23
enGene reports FY net loss of USD 117.3 million, more than double year-on-year
enGene Holdings Inc - Cash and Marketable Securities Plus Proceeds From Nov Financing Expected to Provide Cash Runway Into 2H 2028
THOMSON REUTERS  ·  2025-12-23
enGene Holdings Inc - Cash and Marketable Securities Plus Proceeds From Nov Financing Expected to Provide Cash Runway Into 2H 2028
Press Release: enGene Reports Full Year 2025 Financial Results and Provides Business Update
Dow Jones  ·  2025-12-23
Press Release: enGene Reports Full Year 2025 Financial Results and Provides Business Update
EnGene Says US FDA Selects Detalimogene for Manufacturing Pilot Program
MT Newswires Live  ·  2025-12-02
EnGene Says US FDA Selects Detalimogene for Manufacturing Pilot Program
BRIEF-Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing Readiness
Reuters  ·  2025-12-02
BRIEF-Engene’S Detalimogene Selected For FDA Manufacturing Pilot Program To Support Manufacturing Readiness
enGene Reports 62% Complete Response Rate for Detalimogene in Bladder Cancer Trial
Reuters  ·  2025-12-02
enGene Reports 62% Complete Response Rate for Detalimogene in Bladder Cancer Trial
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
THOMSON REUTERS  ·  2025-12-02
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
enGene Holdings - FDA Selects Detalimogene Voraplasmid to Participate in Chemistry, Manufacturing, & Controls Development & Readiness Pilot Pprogram
THOMSON REUTERS  ·  2025-12-02
enGene Holdings - FDA Selects Detalimogene Voraplasmid to Participate in Chemistry, Manufacturing, & Controls Development & Readiness Pilot Pprogram
enGene Holdings Inc. to Present at Piper Sandler 37th Annual Healthcare Conference
Reuters  ·  2025-11-25
enGene Holdings Inc. to Present at Piper Sandler 37th Annual Healthcare Conference
enGene Holdings Files For Offering Of Common Shares, Size Not Disclosed - SEC Filing
Reuters  ·  2025-11-20
enGene Holdings Files For Offering Of Common Shares, Size Not Disclosed - SEC Filing
enGene Holdings Inc : Leerink Partners Cuts Target Price to $19 From $21
THOMSON REUTERS  ·  2025-11-14
enGene Holdings Inc : Leerink Partners Cuts Target Price to $19 From $21
enGene Holdings (ENGN) Valuation in Focus Following Promising Phase 2 Bladder Cancer Trial Results
Simply Wall St.  ·  2025-11-14
enGene Holdings (ENGN) Valuation in Focus Following Promising Phase 2 Bladder Cancer Trial Results
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Thursday Amid Expected Economic Data Gaps
MT Newswires Live  ·  2025-11-13
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Thursday Amid Expected Economic Data Gaps
EnGene Prices $130 Million Offering of Common Shares, Warrants
MT Newswires Live  ·  2025-11-13
EnGene Prices $130 Million Offering of Common Shares, Warrants
BRIEF-Engene Holdings Prices 12,558,823 Common Shares At $8.50 Per Share
Reuters  ·  2025-11-13
BRIEF-Engene Holdings Prices 12,558,823 Common Shares At $8.50 Per Share
enGene Holdings Inc - Pricing of 12,558,823 Common Shares at a Public Offering Price of $8.50 per Share
THOMSON REUTERS  ·  2025-11-13
enGene Holdings Inc - Pricing of 12,558,823 Common Shares at a Public Offering Price of $8.50 per Share
Could a Shift in enGene (ENGN) Trial Endpoints Reveal New Priorities in Its Clinical Strategy?
Simply Wall St.  ·  2025-11-13
Could a Shift in enGene (ENGN) Trial Endpoints Reveal New Priorities in Its Clinical Strategy?
EnGene Launches Offering of Common Shares
MT Newswires Live  ·  2025-11-13
EnGene Launches Offering of Common Shares

Introduction

Company Name.
ENGENE HOLDINGS INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Issue price:
--